Urteste SA (URT) - Net Assets
Based on the latest financial reports, Urteste SA (URT) has net assets worth zł21.64 Million PLN (≈ $5.96 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł40.74 Million ≈ $11.21 Million USD) and total liabilities (zł19.10 Million ≈ $5.26 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Urteste SA to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł21.64 Million |
| % of Total Assets | 53.12% |
| Annual Growth Rate | 82.32% |
| 5-Year Change | 1666.32% |
| 10-Year Change | N/A |
| Growth Volatility | 262.12 |
Urteste SA - Net Assets Trend (2019–2024)
This chart illustrates how Urteste SA's net assets have evolved over time, based on quarterly financial data. Also explore URT asset base for the complete picture of this company's asset base.
Annual Net Assets for Urteste SA (2019–2024)
The table below shows the annual net assets of Urteste SA from 2019 to 2024. For live valuation and market cap data, see URT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł24.11 Million ≈ $6.64 Million |
-13.09% |
| 2023-12-31 | zł27.74 Million ≈ $7.64 Million |
+393.56% |
| 2022-12-31 | zł5.62 Million ≈ $1.55 Million |
-41.98% |
| 2021-12-31 | zł9.69 Million ≈ $2.67 Million |
+609.71% |
| 2020-12-31 | zł1.37 Million ≈ $375.68K |
+14.20% |
| 2019-12-31 | zł1.20 Million ≈ $328.95K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Urteste SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 326626400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł141.00K | 0.58% |
| Other Comprehensive Income | zł1.87 Million | 7.77% |
| Other Components | zł25.73 Million | 106.71% |
| Total Equity | zł24.11 Million | 100.00% |
Urteste SA Competitors by Market Cap
The table below lists competitors of Urteste SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Raimon Land Public Company Limited
BK:RML
|
$18.06 Million |
|
Bukit Jalil Global Acquisition 1 Ltd. Ordinary Shares
NASDAQ:BUJA
|
$18.09 Million |
|
Conifer Holding Inc
NASDAQ:CNFR
|
$18.09 Million |
|
Lighting and Equipment Public Company Limited
BK:L&E
|
$18.10 Million |
|
Vereinigte Filzfabriken AG
MU:VFF
|
$18.05 Million |
|
Trinity Watthana Public Company Limited
BK:TNITY
|
$18.04 Million |
|
Mountain Alliance AG
XETRA:ECF
|
$18.04 Million |
|
Deltamac Taiwan Co Ltd
TWO:6144
|
$18.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Urteste SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 27,743,000 to 24,111,000, a change of -3,632,000 (-13.1%).
- Net loss of 3,631,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-3.63 Million | -15.06% |
| Other Changes | zł-1.00K | -0.0% |
| Total Change | zł- | -13.09% |
Book Value vs Market Value Analysis
This analysis compares Urteste SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.41x to 2.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | zł2.01 | zł43.00 | x |
| 2020-12-31 | zł1.13 | zł43.00 | x |
| 2021-12-31 | zł9.21 | zł43.00 | x |
| 2022-12-31 | zł4.95 | zł43.00 | x |
| 2023-12-31 | zł21.46 | zł43.00 | x |
| 2024-12-31 | zł17.10 | zł43.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Urteste SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -201.72%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.23x
- Recent ROE (-15.06%) is above the historical average (-40.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -30.52% | 0.00% | 0.00x | 1.04x | zł-484.26K |
| 2020 | -78.63% | 0.00% | 0.00x | 2.05x | zł-597.66K |
| 2021 | -23.97% | 0.00% | 0.00x | 1.03x | zł-3.29 Million |
| 2022 | -72.23% | -135333.33% | 0.00x | 1.19x | zł-4.62 Million |
| 2023 | -20.13% | -420.00% | 0.04x | 1.07x | zł-8.36 Million |
| 2024 | -15.06% | -201.72% | 0.06x | 1.23x | zł-6.04 Million |
Industry Comparison
This section compares Urteste SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $62,363,474
- Average return on equity (ROE) among peers: -161.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Urteste SA (URT) | zł21.64 Million | -30.52% | 0.88x | $18.06 Million |
| Bioton S.A. (BIO) | $255.42 Million | 13.56% | 0.40x | $102.09 Million |
| Captor Therapeutics S.A. (CTX) | $96.32 Million | -37.26% | 0.17x | $118.10 Million |
| Mabion S.A. (MAB) | $3.73 Million | -1497.08% | 23.47x | $33.54 Million |
| Molecure S.A. (MOC) | $81.89 Million | -4.61% | 0.05x | $30.34 Million |
| Nanogroup SA (NNG) | $-252.70K | 0.00% | 0.00x | $20.63 Million |
| Pharmena S.A. (PHR) | $-6.79 Million | 0.00% | 0.00x | $10.42 Million |
| PolTREG S.A. (PTG) | $87.52 Million | -15.48% | 0.45x | $25.28 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $-2.89 Million | 0.00% | 0.00x | $5.46 Million |
| Ryvu Therapeutics SA (RVU) | $3.13 Million | -76.24% | 4.75x | $120.64 Million |
| Synthaverse S.A. (SVE) | $105.56 Million | 5.76% | 0.55x | $62.77 Million |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.